These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 33995121)

  • 1. Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.
    Suvarna K; Biswas D; Pai MGJ; Acharjee A; Bankar R; Palanivel V; Salkar A; Verma A; Mukherjee A; Choudhury M; Ghantasala S; Ghosh S; Singh A; Banerjee A; Badaya A; Bihani S; Loya G; Mantri K; Burli A; Roy J; Srivastava A; Agrawal S; Shrivastav O; Shastri J; Srivastava S
    Front Physiol; 2021; 12():652799. PubMed ID: 33995121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma proteomics identify potential severity biomarkers from COVID-19 associated network.
    Sahin AT; Yurtseven A; Dadmand S; Ozcan G; Akarlar BA; Kucuk NEO; Senturk A; Ergonul O; Can F; Tuncbag N; Ozlu N
    Proteomics Clin Appl; 2023 Mar; 17(2):e2200070. PubMed ID: 36217943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal proteomic profiling provides insights into host response and proteome dynamics in COVID-19 progression.
    Lee JS; Han D; Kim SY; Hong KH; Jang MJ; Kim MJ; Kim YG; Park JH; Cho SI; Park WB; Lee KB; Shin HS; Oh HS; Kim TS; Park SS; Seong MW
    Proteomics; 2021 Jun; 21(11-12):e2000278. PubMed ID: 33945677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients.
    Alaiya A; Alshukairi A; Shinwari Z; Al-Fares M; Alotaibi J; AlOmaim W; Alsharif I; Bakheet R; Alharbi L; Allam R; Asiri A; Memish Z; Alromaih K; Al-Mozaini M
    J Inflamm Res; 2021; 14():4313-4328. PubMed ID: 34511970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVIDpro: Database for mining protein dysregulation in patients with COVID-19.
    Zhang F; Luna A; Tan T; Chen Y; Sander C; Guo T
    bioRxiv; 2022 Sep; ():. PubMed ID: 36203550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multi-omics Longitudinal Study Reveals Alteration of the Leukocyte Activation Pathway in COVID-19 Patients.
    Suvarna K; Salkar A; Palanivel V; Bankar R; Banerjee N; Gayathri J Pai M; Srivastava A; Singh A; Khatri H; Agrawal S; Shrivastav O; Shastri J; Srivastava S
    J Proteome Res; 2021 Oct; 20(10):4667-4680. PubMed ID: 34379420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking of Machine Learning classifiers on plasma proteomic for COVID-19 severity prediction through interpretable artificial intelligence.
    Dimitsaki S; Gavriilidis GI; Dimitriadis VK; Natsiavas P
    Artif Intell Med; 2023 Mar; 137():102490. PubMed ID: 36868685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive proteomic analysis reveals distinct functional modules associated with skull base and supratentorial meningiomas and perturbations in collagen pathway components.
    Mukherjee S; Biswas D; Epari S; Shetty P; Moiyadi A; Ball GR; Srivastava S
    J Proteomics; 2021 Aug; 246():104303. PubMed ID: 34174477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients.
    Park J; Kim H; Kim SY; Kim Y; Lee JS; Dan K; Seong MW; Han D
    Sci Rep; 2020 Dec; 10(1):22418. PubMed ID: 33376242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
    Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
    J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer and coronary disease pathways.
    Wang L; Western D; Timsina J; Repaci C; Song WM; Norton J; Kohlfeld P; Budde J; Climer S; Butt OH; Jacobson D; Garvin M; Templeton AR; Campagna S; O'Halloran J; Presti R; Goss CW; Mudd PA; Ances BM; Zhang B; Sung YJ; Cruchaga C
    medRxiv; 2022 Jul; ():. PubMed ID: 35923315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches.
    Mukherjee A; Verma A; Bihani S; Burli A; Mantri K; Srivastava S
    Drug Discov Today Technol; 2021 Dec; 39():1-12. PubMed ID: 34906319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.
    Anisul M; Shilts J; Schwartzentruber J; Hayhurst J; Buniello A; Shaikho Elhaj Mohammed E; Zheng J; Holmes M; Ochoa D; Carmona M; Maranville J; Gaunt TR; Emilsson V; Gudnason V; McDonagh EM; Wright GJ; Ghoussaini M; Dunham I
    Elife; 2021 Aug; 10():. PubMed ID: 34402426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive nasopharyngeal proteomics of COVID-19 patient identify abnormalities related to complement and coagulation cascade and mucosal immune system.
    Ayass MA; Cao W; Zhang J; Dai J; Zhu K; Tripathi T; Griko N; Pashkov V; Abi-Mosleh L
    PLoS One; 2022; 17(9):e0274228. PubMed ID: 36094909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.
    Villar M; Urra JM; Rodríguez-Del-Río FJ; Artigas-Jerónimo S; Jiménez-Collados N; Ferreras-Colino E; Contreras M; de Mera IGF; Estrada-Peña A; Gortázar C; de la Fuente J
    Front Immunol; 2021; 12():730710. PubMed ID: 34566994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Use of Serum Proteomics for Monitoring COVID-19 Progression to Complement RT-PCR Detection.
    Zhang Y; Cai X; Ge W; Wang D; Zhu G; Qian L; Xiang N; Yue L; Liang S; Zhang F; Wang J; Zhou K; Zheng Y; Lin M; Sun T; Lu R; Zhang C; Xu L; Sun Y; Zhou X; Yu J; Lyu M; Shen B; Zhu H; Xu J; Zhu Y; Guo T
    J Proteome Res; 2022 Jan; 21(1):90-100. PubMed ID: 34783559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new hybrid ensemble machine-learning model for severity risk assessment and post-COVID prediction system.
    Shakhovska N; Yakovyna V; Chopyak V
    Math Biosci Eng; 2022 Apr; 19(6):6102-6123. PubMed ID: 35603393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Label-free plasma proteomics for the identification of the putative biomarkers of oral squamous cell carcinoma.
    Gautam SS; Singh RP; Karsauliya K; Sonker AK; Reddy PJ; Mehrotra D; Gupta S; Singh S; Kumar R; Singh SP
    J Proteomics; 2022 May; 259():104541. PubMed ID: 35231661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Investigation of COVID-19 Severity During the Tsunamic Second Wave in Mumbai.
    Rajoria S; Nair D; Suvarna K; Pai MGJ; Salkar A; Palanivel V; Verma A; Barpanda A; Awasthi G; Doshi H; Dhara V; Burli A; Agrawal S; Shrivastav O; Shastri J; Srivastava S
    Adv Exp Med Biol; 2023; 1412():175-195. PubMed ID: 37378767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.